In January 2018, Perrigo received tentative approval from the FDA for ivermectin cream,1%, developed in
collaboration with Sol-Gel. Perrigo was second to file and, as of today,there is no public disclosure of a third filer to the FDA. In February 2019, Perrigo received approval from the FDA and launched the sale of acyclovir cream,5%, developed
in collaboration with Sol-Gel. An authorized generic product entered the market in the third quarter of 2019. Bioequivalence achieved for generic 5-fluorouracil cream, 5%, for actinic keratosis, submission of abbreviated New Drug Application
expected in 1H 2021. A portfolio of generic product candidates with favorable commercial agreementsthat supplement our branded pipelineSeven collaborations with Perrigo and 1 with Douglas Pharmaceuticalswith 50/50 gross profit sharing FDA
Approvals Recent Developments Multiple Collaborations Revenue-generating generics partnerships